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stefledi2000@yahoo.com th th tumors observed in early childhood. The phase of proliferation, followed by a phase of slow, spontaneous regression after the age of Most hemangiomas are uncomplicated and needed if the hemangioma is located at certain body sites, such as the face, or if it results in a functional handicap, such as limitation of eye opening. In addition, ulcerated, rapidly growing hemangiomas 3 with hemangiomas. Additional complications due 4 different dressings, compresses or topical antibiotics have been used as treatments, but ulcerated hemangiomas have also been reported to respond to therapy with steroids, chemotherapeutic agents, interferon and propranolol. 5 hemangiomas who underwent propranolol propranolol has rapidly entered the field of hemangioma therapy. safe, with high efficiency and acceptable toxicity.
of propranolol for hemangioma treatment was is still speculative. Oral corticosteroids have been used to treat problematic infantile hemangiomas for decades and steroids have many side effects, so physicians have sought other treatments. More recently, the use of propranolol, a heart medication, was serendipitously appears to have fewer side effects than steroids, but its as a treatment of choice, in terms of efficacy and safety, to manage ulcerated hemangiomas, in place of corticosteroids.
Manado, who were treated with propranolol.
Case Report
The first case was an 8-month-old boy with an ulcerated hemangioma on the right cubital fossa (Figure 1) . The hemangioma was first observed when the patient was 3 month old, after which it proliferated in size. No other hemangiomas were found in this patient.
hemangioma at the left thoracic region, measuring
The hemangioma was noticed immediately 3 days after birth and it proliferated thereafter. No other hemangiomas were found in this patient.
No treatment was initiated for the hemangiomas in either patient until the ulcerations occurred. measurements, serum electrolytes, and blood glucose tests were performed. All results were normal in both patients.
hemangiomas in both patients were lighter in color, smaller in size, and less ulcerated. No side effects from propranolol treatment were experienced by either patient. Durations of propranolol treatment until the last follow-up visit were 5 months for the first case and 3 months for the second case. The characteristics of case subjects are shown in Table 1 .
Methods

TM
infantile hemangioma, propranolol, and corticosteroid. The search was limited to human studies in children titles or abstracts, as well as published case reports, randomized clinical trials, meta-analyses, and systematic studies.
Through this filtering method, 32 articles were initially found that fulfilled the criteria. Further investigation was manually carried out in the relevant 
Results
et al did a meta-analysis on the effectiveness of propranolol versus different therapies for treating infantile airway hemangiomas. 9 Random-effect, metaan effective intervention for the resolution of infantile the effectiveness of propranolol versus steroids, CO 2 laser treatment, or vincristine, showed propranolol to be the most effective treatment ( Table 2) .
Four case reports concluded that propranolol was a highly effective and safe, new treatment modality for ulcerated hemangioma in infants.
and duration of therapy, as well as side effects and et al 11 concluded that propranolol appeared to be an effective treatment option for infantile hemangioma, even in the non-proliferative phase and after the first hypoglycemia, bronchospasms, and hypotension. Of 28 patients, 2 patients had symptomatic hypoglycemia, symptomatic hypotension, and 3 patients had bronchial hyperactivity.
A follow-up report on 32 children showed per day had a consistent, rapid, therapeutic effect.
the natural course of infantile hemangiomas, and days, ultrasound examinations showed regression in t et al concluded from their retrospective study that propranolol was useful as a first-line or single-agent treatment of facial infantile hemangioma in children. It showed minimal side effects compared to steroid treatment. Only 2 tolerated the drug well when it was reintroduced at a later time.
Discussion
A thorough discussion of the management of infantile their natural history, as well as what they are their associated with and potential complications. In general, hemangiomas are not present at birth, but appear shortly afterward. In some cases, a precursor Ulceration may also be the cause of permanent, unsightly scars. Therefore, ulcerated hemangiomas presence of any functional discomfort. In addition to therapy aiming to stop proliferation and further ulceration, supportive therapy such as local wound care, or administration of pain medications and antibiotics may be necessary. In eight review articles, propranolol, a nonselective was recently introduced as novel modality for the treatment of proliferating hemangiomas.
2-adrenergic receptors. Leaute-Labreze et al first reported the effectiveness of propranolol for the treatment of children with severe infantile hemangiomas, which improved after the first day of treatment. After this report, many physicians have used propranolol for infantile hemangiomas.
for severe or complicated infantile hemangiomas, achieving rapid and significant reduction in their sizes. This reduction was mainly achieved during the inducing a less dramatic therapeutic effect. In our cases, Our two ulcerated hemangioma patients underwent treatment with propranolol as first-line courses demonstrated that propranolol may be an option in the treatment of ulcerated hemangiomas. Our cases showed success of therapy with propranolol et al who gave detailed information about the course of disease under this new treatment option.
either case. The pre-treatment assessment and the safety of 9-Nevertheless, no serious complications with the therapy have been reported, and may have a better safety profile than previously used therapy for the treatment of proliferating hemangiomas.
infantile hemangiomas can be attributed to three up-regulation of apoptosis of capillary endothelial cells. They correspond to early (brightening of hemangioma surface), intermediate (growth arrest), and long-term (regression) clinical observations. Apoptosis is not complete, as partial regrowth of hemangiomas after discontinuation of propranolol has been observed. clinical experience no serious cardiovascular event has been recorded for children on chronic therapy. 22 Complications from propranolol treatment of infantile hemangiomas reported so far (hypotension, sinus bradycardia, and hypoglycemia) 23 were not lifethreatening, but certainly warrant careful monitoring of all infants with infantile hemangiomas before and during propranolol therapy.
patients, but this low sample number does not allow us to draw firm conclusions about the efficacy of propranolol for ulcerated infantile hemangiomas. one month of therapy. It was our impression that propranolol was helpful for treatment of ulcerated infantile hemangiomas, but we had no control group for comparison. Based on our experience, fast-acting as corticosteroids. The duration of propranolol therapy is not well established, and possible regrowth of infantile hemangioma after propranolol withdrawal needs to be assessed in longterm studies. The optimal dosage of propranolol for et al gradually increased the dosage of propranolol
et al
The potential side effects of hypoglycemia. patients with asthma, and it is not recommended during episodes of bronchiolitis. A propranolol dosage events. None of our patients had symptoms of hypoglycemia, although glucose levels were monitored patients, warning of future subjects to the possibility of hypoglycemia may be necessary. Neither of our patients had hypotension that might have led us to reduce the dose.
The appropriate monitoring protocol for evaluation of infants with infantile hemangiomas before and during propranolol treatment has been count, blood glucose, and serum electrolyte levels.
In children with conflicting results or those at
Monitoring blood pressure and heart rate during the first days of treatment are also recommended. Clinical signs of low glucose levels should be sought, and parents must be advised to help their child hypoglycemia may have untoward effects on a developing brain. effects of propranolol, regularly scheduled follow-up visits should be established.
in the management of ulcerated hemangiomas. Oral effective, and safe in the treatment of infantile hemangiomas. Further studies are needed to establish the optimal dose of propranolol and the appropriate duration of treatment, as well as the comparative efficacy between propranolol and corticosteroids.
at a tertiary vascular anomalies center. Laryngoscope as first-line treatment for rapidly proliferating infantile
